Axitinib Plus Dalantercept in Advanced Renal Cell Carcinoma
Martin Voss, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that dalantercept in combination with axitinib in patients with advanced renal cell carcinoma did not appear to improve progression-free survival. The results from this randomized phase II DART study were presented at the 2017 International Kidney Cancer Symposium in Miami.
“Due to its lack of efficacy, there is no plan to further develop [the dalantercept] program in renal cell carcinoma or other diseases,” revealed Dr. Voss at the conference.
Dalantercept, an ALK1 receptor fusion protein that acts as a ligand trap, has displayed strong antitumor activity in previous studies. The investigators randomized 119 patients to receive dalantercept plus axitinib or axitinib plus placebo.
The median progression-free survival was 6.8 months for the dalantercept group versus 5.6 months for the placebo group. The rate of disease progression or death did not seem to decrease with the addition of dalantercept. Furthermore, the investigators did not find any significant differences between the dalantercept and placebo arms regarding objective response rates (19% vs. 25%) or grade 3 or higher adverse events (59% vs. 64%).